Gulf study reveals Real-World use of palbociclib for advanced breast cancer

NCT ID NCT04916509

First seen Jun 07, 2026 · Last updated Jun 16, 2026 · Updated 1 time

Summary

This study reviewed medical records of 258 adults in Gulf countries (like Saudi Arabia and UAE) who took palbociclib for advanced HR+/HER2- breast cancer. Researchers collected information on patient characteristics, treatment patterns, and outcomes like how long the cancer stayed under control. The goal was to understand real-world use, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dubai Hospital

    Dubai, United Arab Emirates

  • Hamad Medical Corporation

    Doha, Qatar

  • King Abdulaziz Medical City National Guard Hospital

    Jeddah, 22384, Saudi Arabia

  • King Abdulaziz Medical City National Guard Hospital Riyahd

    Riyadh, 11426, Saudi Arabia

  • King Saud University Medical City Riyadh PO BOX 7805

    Riyadh, 11472, Saudi Arabia

  • Mediclinic City Hospital

    Dubai, United Arab Emirates

  • Tawam

    Al Ain City, United Arab Emirates

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.